Tenaris heads into its August 5 earnings report with the Street's most-watched voice freshly in its corner, yet the options market suggesting investors are leaning bullish rather than defensive.
The most consequential recent move belongs to Morgan Stanley, whose analyst upgraded Tenaris to Equal-Weight from Underweight on July 15 — less than three weeks before the print — lifting the price target from $53 to $65 in the process. That shift matters because the same firm had been a consistent bear, maintaining Underweight with a $40 target as recently as February before nudging it to $50 in April. The reversal brings Morgan Stanley closer to where Barclays has been sitting all year: the firm maintains Overweight with an $82 target, raised from $78 after the last earnings release in May. The mean consensus target now sits at $64.29, implying roughly 12% upside from the current price of $57.33 — a modest gap that reflects a market still working out how much credit to give the story. Bulls point to a strong Argentine and Suriname backlog building into 2026 and an OCTG pricing inflection; bears counter that EBITDA estimates have been largely stagnant and that flat steel input prices cap the upside on tubular goods margins.
Options positioning adds texture to that debate, and it tilts toward confidence rather than caution. The put/call ratio has dropped to 0.61, running about one standard deviation below its 20-day average of 0.71 — meaning call demand has been gaining relative to puts through July. That shift is notable given the PCR was sitting near 0.86 in early July and has compressed steadily since, coinciding with the Morgan Stanley upgrade and the stock's 3.3% rise over the past month to $57.33. Short positioning meanwhile poses no meaningful friction. Estimated short interest has drifted down roughly 3% over the past week to around 4.5 million shares, and borrow availability is ample at 475%, with a cost to borrow that has eased nearly 30% over the week to just 0.41% annually — conditions that offer no particular incentive to cover ahead of the number.
Past earnings reactions give context worth noting. The two most recent quarterly prints both saw the stock fall sharply on the day — down 7.1% in May and 4.2% in the prior quarter — before recovering to near-flat over five sessions. The February print was the exception: a 5.1% one-day gain that extended to a 9.4% five-day move, suggesting the stock can deliver when results genuinely surprise. That pattern — day-one pain, short-lived — has given patient holders some comfort, but also means the initial reaction window will be watched closely.
The August 5 report is therefore less about whether Tenaris is positioned for long-term growth and more about whether the Argentine and Suriname backlog is translating into near-term volume and pricing that can move those stagnant EBITDA estimates — a test of whether the Morgan Stanley upgrade was premature or prescient.
See the live data behind this article on ORTEX.
Open TS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Tenaris heads into its May 6 Q1 results with short sellers actively retreating — making the earnings print a test of whether the bullish momentum can survive contact with the numbers. The short-selling exodus is the…
Why this matters — Three distinct ORTEX data streams aligned on TS within 24 hours: cost to borrow jumped 54%, options sentiment spiked, and short interest fell 21% over the month. The convergence suggests shifting…
